Fracture-risk calculators: Has their time come?
- The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Hooven, F. H.; Adachi, J. D.; Adami, S.; Boonen, S.; Compston, J.; Cooper, C.; Delmas, P.; Diez-Perez, A.; Gehlbach, S. L.; Greenspan, S.; LaCroix, A.; Lindsay, R.; Netelenbos, J. C.; Pfeilschifter, J.; Roux, C.; Saag, K. G.; Sambrook, P.; Silverman, S.; Siris, E.; Watts, N. B. // Osteoporosis International;Jul2009, Vol. 20 Issue 7, p1107
The Global Longitudinal study of Osteoporosis in Women (GLOW) is a prospective cohort study involving 723 physicians and 60,393 women subjects â‰¥55 years. The data will provide insights into the management of fracture risk in older women over 5 years, patient experience with prevention and...
- Patterns of Anti-Osteoporosis Medication Use among Women at High Risk of Fracture: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Gehlbach, Stephen; Hooven, Frederick H.; Wyman, Allison; Diez-Perez, Adolfo; Adachi, Jonathan D.; Luo, Xuemei; Bushmakin, Andrew G.; Anderson, Frederick A. // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1
Objective: To assess patterns of anti-osteoporosis medication (AOM) use over 3 years among women at high risk of major fracture. Methods: The GLOW registry follows a cohort of more than 40,000 women aged â‰¥55 from 615 primary care practices in 10 countries. Self-administered surveys...
- FRAX(r) version 3.6 released with 5 new country models. // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1
The article informs that the Fracture Risk Assessment Tool version 3.6 developed by the World Health Organization has been released in additional countries including Chile, Greece and Indonesia.
- Denosumab: Fracture risk reduced in high-risk subset in FREEDOM. Alexander, Walter; Kalvaitis, Katie // Endocrine Today;Oct2009, Vol. 7 Issue 12, p17
The article focuses on a study which examined the efficacy of denosumab in reducing fracture risk in postmenopausal women with osteoporosis.
- FRAX(r) version 3.6 released with 5 new country models. // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1
The article informs that the World Health Organization (WHO) has launched version 3.6 of its Fracture Risk Assessment Tool, FRAX with new country models for Chile, Greece, Indonesia, Ireland and Lithuania and Greek as an additional language option.
- The importance of patient clubs in the management of osteoporotic patients. Gaál, János; Farkas, László; Bender, Tamás; Somogyi, Péter // Central European Journal of Medicine;Dec2011, Vol. 6 Issue 6, p821
Although the significance of osteoporosis is well known worldwide, the number of patients undergoing therapy for this disease corresponds to a fraction only of the optimal proportion. In many countries, patients at a high risk of fracture - including those who have in fact sustained a typical...
- The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAXÂ®. Borgström, F.; Ström, O.; Coelho, J.; Johansson, H.; Oden, A.; McCloskey, E.; Kanis, J. // Osteoporosis International;Mar2010, Vol. 21 Issue 3, p495
The study estimated the cost-effectiveness of risedronate compared to no treatment in UK women using the FRAX algorithm for fracture risk assessment. A Markov cohort model was used to estimate the cost-effectiveness. Risedronate was found cost-effective from the age of 65 years, assuming a...
- Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naÃ¯ve postmenopausal women. Kuo-Chiang Lian; Lang, Thomas F.; Keyak, Joyce H.; Modin, Gunnard W.; Rehman, Qaisar; Loi Do; Lane, Nancy E. // Osteoporosis International;Jun2005, Vol. 16 Issue 6, p642
Chronic treatment with glucocorticoids (GCs) leads to significant bone loss and increased risk of fractures. In chronically GC-treated patients, hip fracture risk is nearly 50%. The purpose of this investigation was to determine if there are differences in the quantities of trabecular and...
- Ten-year fracture probability identifies women who will benefit from clodronate therapy–additional results from a double-blind, placebo-controlled randomised study. McCloskey, E. V.; Johansson, H.; Oden, A.; Vasireddy, S.; Kayan, K.; Pande, K.; Jalava, T.; Kanis, J. A. // Osteoporosis International;May2009, Vol. 20 Issue 5, p811
Fracture risk prediction can be enhanced by the concurrent assessment of other clinical risk factors. This study demonstrates that the estimation of an individualâ€™s 10-year probability of fracture by the FRAXÂ® algorithm identifies patients at high risk of fracture who will respond to...